ProQR Therapeutics BV (PRQR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, ProQR Therapeutics BV (PRQR) has a cash flow conversion efficiency ratio of -0.214x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.23 Million) by net assets ($57.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ProQR Therapeutics BV net asset quality index to measure how much of total assets are equity-financed.
ProQR Therapeutics BV - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how ProQR Therapeutics BV's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check ProQR Therapeutics BV cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
ProQR Therapeutics BV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ProQR Therapeutics BV ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bogazici Beton Sanayi ve Ticaret AS
IS:BOBET
|
0.087x |
|
Goodbaby International Holdings Limited
F:GBH
|
0.041x |
|
Holmes Place International Ltd
TA:HLMS
|
0.258x |
|
ProCap Financial, Inc.
NASDAQ:BRR
|
-0.011x |
|
Aurora World Corporation
KQ:039830
|
0.003x |
|
Portman Ridge Finance Corp
NASDAQ:PTMN
|
-0.003x |
|
Capitan Silver Corp.
V:CAPT
|
-0.022x |
|
Douglas Elliman Inc
NYSE:DOUG
|
-0.078x |
Annual Cash Flow Conversion Efficiency for ProQR Therapeutics BV (2013–2024)
The table below shows the annual cash flow conversion efficiency of ProQR Therapeutics BV from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see ProQR Therapeutics BV (PRQR) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $88.56 Million | $-36.39 Million | -0.411x | -187.20% |
| 2023-12-31 | $45.72 Million | $21.55 Million | 0.471x | +145.87% |
| 2022-12-31 | $66.68 Million | $-68.51 Million | -1.027x | -347.22% |
| 2021-12-31 | $113.23 Million | $-26.01 Million | -0.230x | +66.23% |
| 2020-12-31 | $69.19 Million | $-47.06 Million | -0.680x | -62.93% |
| 2019-12-31 | $105.33 Million | $-43.97 Million | -0.417x | -26.11% |
| 2018-12-31 | $92.69 Million | $-30.68 Million | -0.331x | +62.75% |
| 2017-12-31 | $39.33 Million | $-34.95 Million | -0.889x | -38.00% |
| 2016-12-31 | $53.14 Million | $-34.22 Million | -0.644x | -138.66% |
| 2015-12-31 | $89.80 Million | $-24.23 Million | -0.270x | -104.21% |
| 2014-12-31 | $109.40 Million | $-14.46 Million | -0.132x | -100.50% |
| 2013-12-31 | $-89.00K | $-2.33 Million | 26.202x | -- |
About ProQR Therapeutics BV
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-sta… Read more